Market Intelligence for Atopic Dermatitis, Netherton Syndrome, Psoriasis, and Ovarian Cancer Programs. Access sequence-verified serine protease antigens, catalytic mutants, and orthogonal assay tools designed for high-selectivity screening against the KLK family.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLK7-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Active) | KLK7 Active Protease High purity (>95%), Endotoxin <1 EU/μg, Sequence Verified, HEK293 Expressed (native folding). Theoretical MW ~27 kDa. |
View KLK7 Products |
| Antigen (Mutant) | KLK7 S195A Catalytic Dead Mutant For binding studies without enzymatic activity. Sequence Verified, >95% purity. |
View KLK7 Products |
| Gene Delivery | KLK7 Promise-ORF / Lentivirus Full-length ORF for stable overexpression in keratinocyte lines (e.g., HaCaT). |
View KLK7 Products |
| Benchmark Ab | Anti-KLK7 Neutralizing Antibody Recombinant positive control for activity neutralization and binding assays. |
View KLK7 Products |
| Validator | KLK7 siRNA Set (3 unique sequences) For knockdown verification, specificity checks, and target engagement confirmation. |
View KLK7 Products |
| Related Target: KLK5 | KLK5 (Stratum Corneum Tryptic Enzyme) Co-regulated serine protease in epidermal desquamation and inflammatory skin pathology. |
View KLK5 Products |
| Related Target: KLK14 | KLK14 (Kallikrein-related Peptidase 14) Close homolog (~40% identity); critical for selectivity counter-screening. |
View KLK14 Products |
| Related Target: SPINK5 | SPINK5 (LEKTI) Endogenous multi-domain inhibitor; loss-of-function drives Netherton syndrome and KLK hyperactivity. |
View SPINK5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| KLK Family Selectivity (KLK5/KLK14 cross-reactivity) | Homolog Panel Available: Human KLK5, KLK14, and KLK7 proteins strictly verified by mass spectrometry (>95% purity) for orthogonal screening. |
| Enzymatic vs. Binding Mechanism Dissection | Catalytic Mutant (S195A) provided as binding-only control; Active WT enzyme with confirmed specific activity (fluorogenic substrate validated). |
| Cellular Context Assays (Keratinocyte models) | Lentivirus Premade Particles for stable KLK7 overexpression in HaCaT cells; Endotoxin controlled (<0.01 EU/μL). |
| Cross-species (cyno/mouse) evaluation | Human / Mouse / Cynomolgus KLK7 recombinant proteins available with >95% purity, sequence verified. |
| False Positives / Off-target siRNA Effects | Validated siRNA Set included for specificity checks; Sequence-verified independent targets. |
Live KLK7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLK7 therapeutics is intensifying, with major players shifting focus from broad immunosuppression to targeted protease modulation in both inflammatory skin diseases (atopic dermatitis, Netherton syndrome, psoriasis) and cancer (ovarian, pancreatic). First-generation small-molecule inhibitors and antisense oligonucleotides (ASO, e.g., Ionis KLK7-LRx) are advancing through early clinical phases. The next wave of R&D is targeting combination strategies with IL-4Rα/IL-13 blockers, JAK pathway modulators, and novel delivery vehicles for RNA-based modalities. Highly specific monoclonal antibodies and advanced targeted degraders aim to achieve precise modulation without pan-kallikrein toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotide (ASO) | Ionis Pharmaceuticals / Novartis | Atopic Dermatitis, Netherton Syndrome | Cell Permeability & Knockdown Efficiency (Need Lentivirus-stable lines for target validation) |
| Small Molecule Inhibitor | Bayer, Dermatology Biotechs | Atopic Dermatitis, Psoriasis, Ovarian Cancer | Enzymatic Inhibition & Selectivity Panel (Need Active KLK7 + KLK5/KLK14 orthologs) |
| Monoclonal Antibody (Topical/Systemic) | Novartis, Early-stage Biotech | Moderate-to-Severe AD, Netherton Syndrome | Neutralizing Activity & Stability (Need high-purity antigen for SPR/BLI) |
| siRNA / RNAi | Ionis (Ligand-Conjugated) | Refractory Skin Disease | Specificity Validation (Need siRNA-resistant mutants for rescue experiments) |
| Peptide / Protein Inhibitor | Specialty Pharma, Rare-disease Groups | Localized Skin Lesions, Netherton Syndrome | Binding Affinity & Proteolytic Stability (Need LEKTI-derived controls & active WT protein) |